"The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene"...
- Bone Marrow Suppression
Inform patients that HYCAMTIN decreases blood cell counts such as white blood cells, platelets, and red blood cells. Advise patients to notify their healthcare provider promptly for fever, other signs of infection (e.g., chills, cough, or burning pain on urination), or bleeding. Inform patients that frequent blood tests will be performed while taking HYCAMTIN to monitor for the occurrence of bone marrow suppression.
- Embryofetal Toxicity
Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected during treatment with HYCAMTIN. Advise females of reproductive potential to use effective contraception during treatment and for 1 month after the last dose of HYCAMTIN. Advise males with a female sexual partner of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of HYCAMTIN [see WARNINGS AND PRECAUTIONS, Use In Specific Populations].
Advise nursing mothers to discontinue breastfeeding during treatment with HYCAMTIN [see Use In Specific Populations].
Advise male and female patients of the potential risk for impaired fertility and possible family planning options [see Use in Specific Populations].
- Asthenia and Fatigue
Advise patients that HYCAMTIN may cause asthenia or fatigue. These symptoms may impair the ability to safely drive or operate machinery.
Last reviewed on RxList: 6/19/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Hycamtin Information
Hycamtin - User Reviews
Hycamtin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.